Wegovy Pill vs. Foundayo
Which Oral GLP-1 Is Right for You?

The New Oral GLP-1 Landscape

For years, the biggest barrier to GLP-1 weight loss treatment was simple: the needle. Weekly injections kept millions of patients who needed treatment from starting it. That changed in late 2025 and early 2026 when two FDA-approved oral GLP-1 pills reached the US market within months of each other.

What They Are

Wegovy® pill (oral semaglutide 25mg) was FDA-approved on December 22, 2025. It contains the same active ingredient as Wegovy injectable — semaglutide — reformulated into a daily tablet using an absorption enhancer (SNAC). It must be taken on an empty stomach, 30 minutes before any food or water.

Foundayo™ (orforglipron) was FDA-approved on April 1, 2026. Orforglipron is a small-molecule GLP-1 receptor agonist — not a peptide like semaglutide. Because it is not a peptide, it requires no special fasting protocol. You can take it any time of day with or without food.

Clinical Trial Data

Wegovy pill (OASIS 4, 64 weeks, n=307):

• 16.6% mean weight loss
• 76.3% of patients lost ≥5% body weight
• 47% lost ≥15% body weight
• 27.9% lost ≥20% body weight

Foundayo (ATTAIN trial, 72 weeks, highest dose 17.2mg):

• ~11.1% mean weight loss
• ~70% of patients achieved ≥5% weight loss
• Side effects: nausea, vomiting, diarrhea (similar to semaglutide)

The Key Difference: Food and Water Restrictions

This is the most practically significant difference.

Wegovy pill: Must be taken on an empty stomach with no food or water for 30 minutes after. This is a real compliance challenge for patients with GERD, shift workers, patients on multiple morning medications, or anyone without a predictable morning routine.

Foundayo: No restrictions. Take it with or without food, with water, at any time of day.

Cost

• Wegovy pill: $149/mo (starting doses through August 2026) → $299/mo higher doses via NovoCare
• Foundayo: $149/mo (starting) → $299/mo (higher doses) via LillyDirect (through December 2026)

Who I Prescribe Each For

Wegovy pill: Patients with predictable morning routines, established cardiovascular disease (for SELECT trial's proven CV risk reduction), or prior success with injectable Wegovy who want oral formulation.

Foundayo: Patients with GERD/acid reflux, shift workers, those on multiple morning medications, or anyone for whom simplicity and flexibility matter most.

Medical disclaimer: Educational content, not medical advice. Consult a physician before starting any prescription medication. Page medically reviewed by Teja V. Surapaneni, MD, MS — Board-Certified Internal Medicine (NV, WA, OR, WI). Last reviewed: May 2026.